RCKT Q2 2022 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$54M

Net Income

-$54M

EPS (Diluted)

$-0.83

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$42M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$432M

Total Liabilities

$44M

Stockholders' Equity

$388M

Cash & Equivalents

$188M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$54M	-$34M	-59.2%
Net Income	-$54M	-$35M	-57.6%